Invitae
United States
272 articles about Invitae
-
Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond
1/7/2019
Delivered more than 302,000 samples, generating revenue of more than $144 million in 2018
-
Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference
11/14/2018
Research highlights frequency of medically actionable variants among secondary findings
-
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018
11/7/2018
Raising annual volume and revenue guidance amid strong performance
-
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
10/29/2018
Part of Invitae's network of partnerships, program supports early diagnosis to help patients and their clinicians make more informed decisions about their health
-
Invitae to announce third quarter 2018 financial results on November 7, 2018
10/24/2018
Invitae Corporation today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018.
-
Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people
10/17/2018
Data presented at annual American Society of Human Genetics meeting
-
Invitae to Present at the Ladenburg Thalmann 2018 Healthcare Conference
9/18/2018
Invitae Corporation today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern / 6:00 a.m. Pacific in New York City.
-
Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018
8/7/2018
Raising annual revenue guidance amid strong quarter performance
-
Invitae to announce second quarter 2018 Financial Results on August 7, 2018
7/24/2018
Invitae Corporation announced that it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
-
Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing
6/13/2018
Approximately 10 Percent of Patients With Genetic Changes Associated with Disease Show Copy Number Variant Changes That May Go Undetected by Traditional Approaches
-
Invitae to Present at the William Blair 2018 Growth Stock Conference
5/30/2018
Invitae Corporation announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference.
-
Invitae to participate in two upcoming investor conferences, the Bank of America Merrill Lynch 2018 Heath Care Conference and the UBS Global Healthcare Conference
5/3/2018
Invitae Corporation announced that Sean George, co-founder and chief executive officer of Invitae, will participate in two upcoming investor conferences.
-
Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)
4/27/2018
Invitae Corporation announced that it is launching a new program with Biogen.
-
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing
4/10/2018
-- Data presented at annual American College of Medical Genetics meeting --
-
Invitae Announces Pricing of Public Offering of Common Stock At $4.50 Per Share
3/28/2018
Invitae Corporation announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share.
-
Invitae Announces Proposed Public Offering of Common Stock
3/26/2018
Invitae Corporation announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.
-
Invitae expands network of patients in rare and ultra-rare diseases
3/22/2018
-- No Stomach for Cancer among five advocacy groups establishing registry networks to connect patients, clinicians and researchers --
-
Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information
3/16/2018
Combining germline and somatic information provides more comprehensive view from diagnosis through treatment.
-
Invitae Reports Over 150% Volume and Over 170% Revenue Growth for 2017
2/13/2018
Invitae today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.
-
Invitae to Announce Fourth Quarter and Year-End 2017 Financial Results on February 12, 2017
1/30/2018
The live webcast of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com.